NO20004667L - Farmasoytisk formulering omfattende et 2-[[(2-pyridinyl)metyl]sulfinyl]benzimidazol med anti-ulcusaktivitet, og en fremgangsmate for fremstilling av en slik formulering - Google Patents

Farmasoytisk formulering omfattende et 2-[[(2-pyridinyl)metyl]sulfinyl]benzimidazol med anti-ulcusaktivitet, og en fremgangsmate for fremstilling av en slik formulering

Info

Publication number
NO20004667L
NO20004667L NO20004667A NO20004667A NO20004667L NO 20004667 L NO20004667 L NO 20004667L NO 20004667 A NO20004667 A NO 20004667A NO 20004667 A NO20004667 A NO 20004667A NO 20004667 L NO20004667 L NO 20004667L
Authority
NO
Norway
Prior art keywords
formulation
sulfinyl
benzimidazole
pyridinyl
methyl
Prior art date
Application number
NO20004667A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004667D0 (no
Inventor
Soeren Bols Pedersen
Helle Kann
Kristian Lund Henriksen
Karen Eichstedt Soerensen
Original Assignee
Hexal As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20004667(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hexal As filed Critical Hexal As
Publication of NO20004667D0 publication Critical patent/NO20004667D0/no
Publication of NO20004667L publication Critical patent/NO20004667L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20004667A 1998-03-20 2000-09-19 Farmasoytisk formulering omfattende et 2-[[(2-pyridinyl)metyl]sulfinyl]benzimidazol med anti-ulcusaktivitet, og en fremgangsmate for fremstilling av en slik formulering NO20004667L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK199800397A DK173431B1 (da) 1998-03-20 1998-03-20 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
PCT/DK1999/000137 WO1999048498A1 (en) 1998-03-20 1999-03-17 Pharmaceutical formulation comprising a 2- [[(2- pyridinyl) methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation

Publications (2)

Publication Number Publication Date
NO20004667D0 NO20004667D0 (no) 2000-09-19
NO20004667L true NO20004667L (no) 2000-11-09

Family

ID=8093069

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004667A NO20004667L (no) 1998-03-20 2000-09-19 Farmasoytisk formulering omfattende et 2-[[(2-pyridinyl)metyl]sulfinyl]benzimidazol med anti-ulcusaktivitet, og en fremgangsmate for fremstilling av en slik formulering

Country Status (20)

Country Link
US (1) US6391342B1 (de)
EP (1) EP1061920B1 (de)
AR (1) AR014753A1 (de)
AT (1) ATE218863T1 (de)
AU (1) AU744596B2 (de)
CA (1) CA2323536C (de)
CZ (1) CZ291943B6 (de)
DE (1) DE69901804T2 (de)
DK (2) DK173431B1 (de)
EA (1) EA002502B1 (de)
ES (1) ES2177246T3 (de)
HU (1) HU226580B1 (de)
IS (1) IS2265B (de)
NO (1) NO20004667L (de)
NZ (1) NZ507115A (de)
PL (1) PL192437B1 (de)
TR (1) TR200002696T2 (de)
TW (1) TW529951B (de)
WO (1) WO1999048498A1 (de)
ZA (1) ZA200004757B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PT1187601E (pt) 1999-06-07 2005-11-30 Altana Pharma Ag Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido
EP1064938A1 (de) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmazeutische Dosierungsformen zur kontrollierte Wirkstoffabgabe mit mindenstens ein pulsierendem Zeitverlauf
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
AU2127200A (en) * 1999-11-02 2001-05-14 Cipla Limited A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereofand a process of preparing thereof
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004089333A2 (en) * 2003-02-28 2004-10-21 Cadila Healthcare Limited A stable benzimidazole formulation
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP5171038B2 (ja) * 2003-10-10 2013-03-27 エティファルム イチョウ・エキスを含む放出持続性の微小顆粒およびそのような顆粒の製造方法
EP1699458A4 (de) * 2003-12-30 2012-04-25 Reddys Lab Ltd Dr Pharmazeutische zusammensetzung
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
CA2558535A1 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
CA2565083C (en) 2004-05-07 2014-07-08 Altana Pharma Ag Novel pharmaceutical dosage form and manufacturing process
JP5563735B2 (ja) * 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
JP2009519943A (ja) * 2005-12-16 2009-05-21 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド イラプラゾールの医薬組成物
WO2007100984A2 (en) * 2006-02-24 2007-09-07 Allergan, Inc. Beads containing pyridin-sulfinyl benzoimidazole sulfonyl phenoxy acetate derivatives
EP2026768B1 (de) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Pharmazeutische formulierung auf mehreren einheiten
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20100239681A1 (en) * 2009-03-20 2010-09-23 Biokey, Inc. Controlled Release Particulates Containing Water-Insoluble Drug
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
EP2319504A1 (de) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Feste pharmazeutische Dosierform
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN103202820B (zh) * 2012-01-11 2016-03-30 浙江亚太药业股份有限公司 一种稳定的兰索拉唑肠溶胶囊及其制备方法
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3544614A4 (de) 2016-11-28 2020-08-05 Lipocine Inc. Orale testosteron-undecanoat-therapie
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
ES2024993A6 (es) 1990-12-31 1992-03-01 Genesis Para La Investigacion Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.
TW209174B (de) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
EP0519144B1 (de) * 1991-06-21 1997-08-13 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. Neues galenisches Verfahren für Omeprazol enthaltende Pellets
SE9200858L (sv) 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
FR2692146B1 (fr) 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
AU4513393A (en) 1992-07-17 1994-02-14 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
ES2087823B1 (es) 1994-07-13 1997-02-16 Estudes Et Richerches Pharma E Formulacion de microgranulos gastroresistentes de omeprazol y su procedimiento de fabricacion.
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
CH687810A5 (de) 1995-05-24 1997-02-28 Mepha Ag Pelletformulierung mit Omeprazol.
DE69631981T2 (de) 1995-09-21 2005-04-14 Pharma Pass Ii Llc, Irvine Lansoprazolhaltige Arzneizusammensetzung und Herstellungsverfahren
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
PT101826A (pt) 1996-02-06 1997-09-30 Medinfar Produtos Farmaceutico Processo para a preparacao de microgranulos contendo omeprazole
EP0968204A1 (de) 1997-03-07 2000-01-05 A/S GEA Farmaceutisk Fabrik Verfahren zur herstellung von 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazolen und dabei verwendbare neue verbindungen

Also Published As

Publication number Publication date
DE69901804T2 (de) 2002-12-12
CZ291943B6 (cs) 2003-06-18
TR200002696T2 (tr) 2000-12-21
NO20004667D0 (no) 2000-09-19
CZ20003458A3 (cs) 2001-03-14
DK173431B1 (da) 2000-10-23
DE69901804D1 (de) 2002-07-18
TW529951B (en) 2003-05-01
EP1061920B1 (de) 2002-06-12
ZA200004757B (en) 2001-05-30
NZ507115A (en) 2002-09-27
DK1061920T3 (da) 2002-07-15
PL192437B1 (pl) 2006-10-31
DK39798A (da) 1999-09-21
IS2265B (is) 2007-07-15
WO1999048498A1 (en) 1999-09-30
ATE218863T1 (de) 2002-06-15
ES2177246T3 (es) 2002-12-01
EP1061920A1 (de) 2000-12-27
AU2714899A (en) 1999-10-18
HU226580B1 (en) 2009-04-28
IS5628A (is) 2000-09-13
CA2323536A1 (en) 1999-09-30
AR014753A1 (es) 2001-03-28
AU744596B2 (en) 2002-02-28
PL342840A1 (en) 2001-07-16
US6391342B1 (en) 2002-05-21
HUP0101178A2 (hu) 2001-08-28
CA2323536C (en) 2009-05-19
EA200000970A1 (ru) 2001-02-26
EA002502B1 (ru) 2002-06-27

Similar Documents

Publication Publication Date Title
NO20004667L (no) Farmasoytisk formulering omfattende et 2-[[(2-pyridinyl)metyl]sulfinyl]benzimidazol med anti-ulcusaktivitet, og en fremgangsmate for fremstilling av en slik formulering
ATE391126T1 (de) Kristalline form des (r)-2-(((3-methyl-4-(2,2,2- trifluorethoxy)-2-pyridinyl)methyl)sulfinyl)-1h benzimidazols
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
NO20005430D0 (no) 1-[(1-substituerte-4-piperidinyl)metyl]-4-piperidinderivater, fremgangsmÕter for fremstilling av disse, medisinske preparater inneholdende dem, og mellomprodukter
NO20015309L (no) 1- (P-tienylbenzyl)-imidazoler som anginotensin-(1-7) reseptoragonister, fremgangsmåte for fremstilling og anvendelse avde samme og farmasöytiske preparater som inneholder nevnteforbindelser
DK0984773T3 (da) Farmaceutisk formulering med omeprazol
IS6265A (is) 3(5)-amínó-pýrasól afleiður, aðferð til að útbúa þær og notkun þeirra sem miðla gegn æxlum
HUP0201711A3 (en) N-indanyl-benzamide derivatives, method for their production, their use and pharmaceutical preparations containing them
NO20021719D0 (no) 6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament
NO20002721L (no) Heterocykliske forbindelser for inhibering av mavesyresekresjon, fremgangsmÕter for deres fremstilling og farmasøytiske preparater derav
EE03568B1 (et) Bensimidasooli derivaadid, nende valmistamismeetod ja kasutamine
NO20013560D0 (no) Polymorfer av telmisartan, fremgangsmåter for fremstilling derav og anvendelse derav for fremstilling av et medikament
TR200000534A3 (tr) Bir ilacin uygulanmasi için metot ve sistem
IL136425A0 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
EE200100422A (et) Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
EG23175A (en) New procedure for obtaining derivatives of 2-(2-(pyridinylmethylsulphinyl)-1H-benzimidazole)
ZA989999B (en) New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole
FR2793688B1 (fr) Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
NO994340D0 (no) FremgangsmÕte for fremstilling av 2-[[(2-pyridinyl)metyl]sulfinyl]-1H-benzimidazoler samt nye forbindelser til anvendelse for dette formÕl
NO994209D0 (no) FremgangsmÕte for fremstilling av 2-[[(2-pyridinyl)metyl]sulfinyl]-1H-benzimidazoler og nye forbindelser til anvendelse for dette formÕl
AU2000258410A8 (en) New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole
NO20016404L (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20013878L (no) (1-fenacy-3-fenyl-3-piperidylety)piperidinderivater, fremgangsmåte for fremstilling derav og farmasöytiske preparaterinneholdende de samme
NO20015848L (no) Polymorfer av et krystallinsk azabicyclo(2,2,2)oktan-3- amincitrat og farmasöytiske preparater derav
NO20015387D0 (no) 6-[[(aryl og heteroaryl)oksy]metyl]naftalen-2- karboksamidderivater, fremstilling og terapeutisk anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application